Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02315326 · ClinicalTrials.gov registry record · Phase 1
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
A Phase 1 study of Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) and Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL), sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 93
- Enrollment target
- 7
- Study locations
NCT02315326 is a Phase 1 study of Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) and Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 93 participants. The trial reports 7 study locations across 2 states.
The verdict
NCT02315326, a Phase 1 study of Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) and Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL), has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 93 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the established first-line chemotherapy regimen rituximab, methotrexate, vincristine, and procarbazine (R-VMP) in order to further refine the first-line induction therapy for PCNSL, as observed by a superior CRR (complete response rate) (ARM D RECRUITING ONLY)
Conditions Studied
Interventions
- DRUG Ibrutinib
- DRUG procarbazine
- DRUG HD- Methotrexate (MTX)
- DRUG Rituximab + HD- Methotrexate (MTX)
Study Locations (7)
New York
- Memorial Sloan Kettering Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2014-12-08 |
| Est. Completion | 2026-01-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02315326
The ClinicalTrials.gov registry entry for NCT02315326 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) appearing as the primary indexed condition, and to 4 interventions - of which Ibrutinib is the first listed.
NCT02315326 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02315326 about?
NCT02315326 is a clinical study titled "Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)". The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the established first-line chemotherapy regimen rituximab, methotrexate, v...
What is the current status of trial NCT02315326?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2014-12-08. Estimated completion is 2026-01-28.
What conditions does trial NCT02315326 study?
This clinical trial studies the following conditions: Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL).
What interventions are being tested in trial NCT02315326?
The interventions under investigation include: Ibrutinib (DRUG), procarbazine (DRUG), HD- Methotrexate (MTX) (DRUG), Rituximab + HD- Methotrexate (MTX) (DRUG).
Who is sponsoring clinical trial NCT02315326?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02315326 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)
All registered trials for this condition
Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.